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ABSTRACT

Maternal, Neonatal, and Feeding Type Factors Associated with
Severity of Necrotizing Enterocolitis

Cheryl A. Miner
Department of Nutrition, Dietetics and Food Science
Master of Science
Objective: To identify statistical associations with necrotizing enterocolitis (NEC) severity as
dichotomized into cases with Bell stage II and III disease.
Study Design: We conducted a retrospective study using eight consecutive years of data from a
multihospital healthcare system analyzed NEC severity (Bell stage II vs. III).
Results: We identified 220 neonates with stage > II who had 225 separate episodes of NEC
(157 stage II and 68 stage III). Those with stage III were born at earlier gestational age
(P<0.0001) and lower birth weight (P<0.0001). Diagnosis of NEC occurred on about the same
day of life in stage II and stage III cases. Those who developed stage III had significantly higher
C-reactive protein (P<0.0001), I/T ratio (P= 0.0005), mean platelet volume (MPV) (P= 0.0001)
and lower pH (P<0.0001) and platelet counts (P<0.0001). Transfusions were more common to
those who progressed to stage III (P<0.0001). Regression analysis indicated higher odds of stage
III in relationship to the volume of RBC transfusions (OR 2.41, {CI 1.85 to 3.11}, P<0.0001)
and pasteurized human milk (PHM) (OR 1.32, {CI 1.07 to 1.62}, P = 0.0089). In contrast,
feeding early mother’s own milk (colostrum) for five days reduced the odds for stage III (OR
0.802, {CI 0.67 to 0.96}, P=0.0170). Those with small bowel resection were less likely to have
received mother’s own milk before NEC (OR 0.94, {CI 0.89 to 0.99}, P = 0.019) and factors
predicting death from NEC were a low pH (OR 2.21, {CI 1.27 to 3.85}, P = 0.0005) and less
colostrum (OR 0.96, {CI 0.94 to 0.99}, P = 0.003).
Conclusions: RBC transfusions and PHM increased the odds for stage III NEC, whereas early
mother’s own milk five days reduced the odds. Mother’s own milk with PHM decreased the risk
for small bowl resection and early mother’s milk decreased the odds for mortality from NEC.
Future research and prospective randomized controlled studies are needed to quantify any
reduction in NEC severity on the basis of decreasing RBC transfusions and increasing early
mother’s own milk or colostrum.
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INTRODUCTION
Necrotizing enterocolitis (NEC) is the most common and devastating inflammatory
gastrointestinal emergency in neonates occurring in 1-3 cases per 1000 live births.(1-3) Most
episodes of NEC are managed successfully using medical intensive care, but certain severe cases
require surgery. Reviews and meta-analyses indicate that NEC cases needing surgery have a
higher mortality rate, higher costs of care, longer hospital stays among survivors,(4) and more
neurodevelopmental impairment (5-7) Thus, if it were possible to somehow prevent NEC cases
from progressing to a point where surgery was needed, outcomes would most likely be better and
costs lower. However, currently the risk factors associated with NEC severity are not well
defined, and it is not clear whether factors associated with severe cases, once identified, could be
modified by clinicians in a way that would lower the prevalence of severe cases needing surgery.
Factors associated with developing NEC, of any stage include low gestational age and
low birth weight, (8-10) but little information is available to explain why some neonates with NEC
go on to stage III while others do not. Thus, the purpose of our study was to identify
demographic, clinical, and laboratory associations with severity of NEC cases. We
hypothesized that factors related to NEC differed for the neonate receiving mother’s own milk
as compared to the formula fed neonate.

METHODS
This study was approved by the Intermountain Healthcare and Brigham Young
University Institutional Review Boards as a retrospective de-identified study not requiring
individual informed consent. Records of neonates born between January 1, 2002 and December
31, 2009 and admitted to an Intermountain Healthcare Newborn Intensive Care Unit were
2

reviewed. Intermountain Healthcare is a not-for-profit healthcare company that owns and
operates 21 hospitals with labor and delivery services in Utah and Idaho.
Records were included if the diagnosis of Bell stage II or III NEC was identified in the
electronic archives. When NEC was identified, radiographic images, radiographic reports,
surgical and pathology reports, and physicians and/or nurses notes pertaining to NEC were
reviewed. The date of NEC diagnosis was defined as the day of gastric suction tube placement.
To document the occurrence of NEC, we used the criteria originally proposed by Bell and
coworkers, (11) then subsequently modified by Walsh et al, (12) and later adopted by the Vermont
Oxford Network.(13) This definition required the presence of one or more of the following three
clinical signs: 1) bilious gastric aspirate or emesis, 2) abdominal distension, 3) occult or gross
blood in stool (no fissure) AND one or more of the following three radiographic findings: 1)
pneumatosis intestinalis, 2) hepato-biliary gas, 3) pneumoperitoneum. Stage II NEC diagnosis
included hepato-biliary gas or pneumatosis intestinalis radiographic findings along with
abdominal distention, bilious gastric aspirate, emesis, occult or gross blood in stool. Stage III
NEC diagnosis included all of the above findings plus pneumoperitoneum.
Maternal and neonatal factors along with feeding types at different time periods prior to
NEC were considered for statistical models. Maternal factors considered included pregnancy
induced hypertension (PIH) and/or HELLP syndrome (a group of symptoms in pregnancy
including hemolysis, elevated liver enzymes and low platelet count), substance abuse, smoker
during pregnancy, smoker in the home, prolonged rupture of membranes (> 18 hours) and race.
Neonatal risk factors included: gender, gestational age, birth weight, Apgar scores at 1 minute
and 5 minutes, birth number (singleton, twin or triplet/quadruplet), anthropomorphic
classification at birth (small, appropriate or large for gestational age), hematocrit > 65 percent
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(within the first three days of life), and NEC day of life. Other neonatal factors included the use
of histamine receptor antagonist, proton pump inhibitors, vasopressors, or nitric oxide within five
days of NEC, positive body fluid cultures within seven days of NEC, and red blood cell (RBC)
and platelet transfusions prior to NEC diagnosis. All transfusions were log transformed (natural
log) for analysis.
All feeding types (including, mother’s own milk, pasteurized human milk (PHM),
formula and fortified mother’s own milk/formula) were recorded prior to developing NEC and
were considered in severity models for NEC. Feedings were grouped into different time periods
as follows: 1) the first three days of life (DOL), 2) the first five DOL, 3) the first 14 DOL, 4) the
first five days of feedings (any DOL) and 5) feedings prior to NEC diagnosis. The volume of
feedings in the different time periods were log transformed for analysis.
All breast feedings were estimated and combined with mother’s own milk feedings. For
neonates < 38 weeks gestational age at birth, breast feedings were recorded as : day of life
(DOL) 1 = 3.5 mL/feeding; DOL 2 - 4 = 5 mL/feeding; DOL 5 = 10 mL/feeding and DOL > 6 =
15 mL/feeding. Estimated breast feedings for neonates > 38 week gestation included: DOL 1 =
3.5 mL/feeding; DOL 2 = 5 mL/feeding; DOL 3 = 12 mL/feeding; DOL 4 = 25 mL/feeding;
DOL 5 = 30 mL/feeding and DOL > 6 = 40 mL/feeding.
Stepwise selection regression models (logistic regression for binary variables) were
developed using SAS (version 9.2, year 2008, Cary NC) which considered the above maternal
factors, neonatal factors, and feeding types in the different time periods. Regression models
included: 1) stage II vs. stage III NEC, 2) selected laboratory values within three days of NEC
diagnosis and 3) outcomes of bowel resection and death due to NEC. In addition, the lowest pH
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(arterial or venous within three days of NEC) was considered in models for the effect on
laboratory values, and odds for bowel resection or death from NEC.
Laboratory values that were recorded included the highest C-reactive protein (CRP),
highest leukocyte count, lowest neutrophil count, highest ratio of immature neutrophils
(metamylocytes and bands) to total neutrophils (segmented neutrophils plus bands plus
metamyeocytes)(14) or I/T neutrophil ratio, lowest pH (arterial or venous), lowest platelet count,
and highest mean platelet volume (MPV). These values were collected three days prior to and
following NEC diagnosis.
Pathological and surgical reports were reviewed to determine the anatomic area and
length of bowel resection. Small bowel resections were grouped as: < 20 cm resected, 20-75 cm
resected and >75 cm resected and numerically scored as 1, 2 and 3. Colonic resections were
grouped into sections: cecum, ascending, transverse, or descending/sigmoid resections.
Descriptive and clinical characteristics as well as stepwise regression models are reported
as number (n), percentages (%), least square means (LSM), standard error of the mean (SEM),
means, adjusted odds ratios (OR), 95% confidence intervals(CI) and r2 values. P values were set
a priori at α = <0.01.

RESULTS
A total of 320 neonates were identified with stage II or III NEC born between January 1,
2002 and December 31, 2009 (Figure 1, Appendix C). Ninety six were born at a nonIntermountain Healthcare hospital and transferred for NEC treatment. These ninety six, as well
as four others born in an Intermountain Healthcare hospital, lacked pre-NEC data essential for
the analysis and therefore were not included in this study leaving 220 neonates with 225 episodes
5

of NEC (157 stage II and 68 episodes of stage III NEC). One patient had three distinct episodes
of stage II NEC, and three patients had one episode of stage II and a subsequent episode of stage
III.
Characteristics of those with stage II and stage III NEC are contrasted in Table 1
(Appendix C). Neonates who developed stage III were born at earlier gestational age and lower
birth weight and with slightly lower 5 minute Apgar score. The diagnosis of NEC occurred on
about the same day of life in stage II vs. stage III cases. No differences were identified in
gender, race, singleton vs. multiple birth number, or any of the maternal factors considered.
Laboratory values during the three day period before NEC were more likely to be
abnormal among those who developed stage III (Table 2, Appendix C). Specifically, the group
that developed stage III had a higher CRP, I/T neutrophil ratio, and mean platelet volume
(MPV), and a lower pH and platelet count. However, neutropenia and leukocytosis were not
more common in one group than the other.
Neonates with stage III NEC had less total feedings and formula but more PHM given
prior to NEC diagnosis. No other differences between feeding types were identified between the
two stages (Table 3, Appendix C). RBC and platelet transfusions were more commonly given to
those who went on to develop stage III NEC (Table 4, Appendix C). For those who developed
stage III, blood and urine cultures were more commonly positive within seven days of NEC. The
use of vasopressors and nitric oxide (within five days of NEC) were more common in those who
went on to stage III; and death and death ascribed to NEC were also much more common in this
group (Table 5, Appendix C).

6

Stage II vs III NEC Model
Factors identified in regression analysis predicting a greater likelihood of stage III vs.
stage II NEC were a greater volume (mL/kg) of RBC transfusions (OR 2.41, {CI 1.85 to 3.11}, P
<0.0001) and a greater volume/kg of pasteurized human milk feedings prior to NEC diagnosis
(OR 1.32, {CI 1.07 to 1.62}, P = 0.009) whereas, factors that predicted a lower likelihood of
stage III included early feedings using mother’s own milk (first five days of feedings) (OR 0.80,
{CI 0.67 to 0.96}, P= 0.0170) and an earlier NEC diagnosis (OR 0.94, {CI 0.91 to 0.97}, P
<0.0001).
Laboratory Value Models
All regression models for selected laboratory values within three days of NEC did not
show any significant findings that were practical or meaningful based on selected maternal,
neonatal, or feeding type factors in different time periods studied.
Bowel Resection Models
A regression model for small bowel resection among stage III NEC neonates showed that
those with no resection were more likely to have received mother’s own milk in combination
with pasteurized human milk prior to NEC diagnosis (OR 0.94, {CI 0.89 to 0.99, P = 0.0194).
There were no significant maternal, neonatal, or feeding type factors in different time periods
associated with colonic bowel resection.
Death from NEC Model
Four factors significantly predicted the likelihood of death from NEC among those that
had stage III disease, namely 1) a low pH (OR 2.21, {CI 1.27 to 3.85}, P = 0.0050), 2) less
percent of early mother’s own milk (first 5 days of feedings) any DOL (OR 0.96, {CI 0.94 to
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0.99}, P=0.003), 3) less total feedings the first 14 DOL (OR 0.62, {CI 0.43 to 0.89}, P = 0.009),
and 4) less formula feedings the first 14 DOL (OR 0.97, {CI 0.94 to 0.99}, P = 0.015).

DISCUSSION
The most significant associations we identified with severe NEC were earlier gestational
age, lower birth weight, and more RBC transfusions before developing NEC. Many reports have
identified an association of RBC transfusions and the development of NEC, (15-19) but this is the
first report demonstrating the association between RBC transfusions and NEC severity. A
recent study indicated that 1) 25-30 percent of NEC cases followed a RBC transfusion, generally
within 6 to 24 hours, 2) neonates with transfusion-associated NEC were generally born at earlier
gestation than those with NEC and no antecedent transfusion, and 3) neonates with transfusionassociated NEC have generally had one or more previous RBC transfusions before the one that
precipitates NEC. (15-19)
The most significant factor protecting from stage III disease in the present study was
early feedings with mother’s own milk. This protective effect was not observed for pasteurized
human milk. In fact, as the log unit of pasteurized human milk increased before NEC diagnosis,
there was a 32% increased likelihood for stage III. Distinct differences exist between
pasteurized human milk and fresh maternal milk. Donor milk is pasteurized to avoid potential
transmission of infectious agents by heating to 62.5 degrees C for 30 minutes (Holder method),
but this process inactivates cellular components of milk, including T and B cells, macrophages,
and neutrophils.(20-22) Concentration of immunoglobulins A and G are significantly reduced, as
8

are lactoferrin, (23-25) lysozymes,(24,26) and erythropoientin(27) interferon-γ, interleukin – 1 beta,
interleukin-10, hepatocyte growth factor,(28) insulin-like factor1 and insulin-like growth factor 2.
(29).

Some growth factors have been reported to be reduced by pasteurization, including insulin-

like growth factor-1 and insulin-like factor-2, (29) However, other factors such as epidermal-like
growth factor (EGF) (30) and transforming growth factor-beta,(30) appear capable of withstanding
this process. As human milk banking increases, it is critical to understand the effect of
pasteurization on immunological components and to improve processing techniques to better
preserve these components.
In contrast, early mother’s own milk (first 5 days of feedings) was associated with a
reduction in odds for severe NEC (stage III). Colostrum as compared to mature maternal milk
has many unique features including higher concentrations of secretory IgA, lactoferrin, antiinflammatory cytokines, oligosaccharides, soluble CD-14, and antioxidants.(31-33) Moreover,
mothers of the most preterm infants produce colostrum with even higher concentrations of many
such factors compared with mothers of term infants.(34-36)
The observation that colostrum may decrease NEC severity, which generally occurs some
three weeks later, is consistent with the recent observations from Gonzalez-Reivera et al. (37) that
NEC may be a consequence of events occurring soon after birth. It may be possible that feeding
colostrum (or lack of) could be such an event.
We found that mother’s own milk in combination with PHM had a protective effect on
small bowel resection, whereas pasteurized human milk alone did not. The model for large
bowel resection showed no maternal, neonatal or feeding type factors that predicted outcome.
We also focused on factors associated with death from NEC and found that early
colostrum feedings for five days decreased the odds of mortality. Recently, Meinzen-Derr et
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al.(38) also demonstrated an association between human milk feedings given the first two weeks
and reduction in death from NEC.
We recognize several limitations of our study, foremost of which are those inherent in
retrospective data analyses including susceptibility to error and bias. Other flaws include the
many factors unknown to us because they were not recorded such as the reasons or timing of
RBC transfusions, differences in feeding practices, differences in the types of fortifiers used, and
why colostrum was available for some neonates and not for others.
In conclusion, we sought to find associations with severe NEC using data from a
multicentered healthcare database. Indeed we observed that neonates who received more RBC
transfusions and less colostrum were more likely to have stage III disease. In addition, those that
received less colostrum increased the odds for death from NEC. It is not clear whether
successful programs to encourage early colostrum feedings would decrease the prevalence and
mortality from stage III NEC in actual practice. Certainly any salutary effect of this practice
could have important beneficial effects for neonates, their families, and society. Continued
ongoing and future investigative efforts are necessary due to high human and economic costs of
stage III NEC disease.
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APPENDIX A: COMPLETE INTRODUCTION AND NECROTIZING
ENTEROCOLITIS LITERATURE REVIEW
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OVERVIEW

Necrotizing enterocolitis (NEC) is the most common gastrointestinal emergency in
neonates. Overall, necrotizing enterocolitis (NEC) rates are between 1-5% for all NICU
admissions and occur in approximately 1-3 cases in 1000 live births.(1-3) However, among infants
with birth weights between 500 and 1500 grams, the rates are approximately 12%.(1,4) Thus,
NEC is a major cause of morbidity and mortality in the very low birth weight premature
neonate.(less than or equal to 1500 grams).(5,6) Due to advances in neonatology, over the past
decade, survival of the smaller, more premature infants has increased, resulting in an increase in
the number of NEC cases. (5) Most episodes of NEC are managed successfully using medical
intensive care, but certain severe cases require surgery. Several reviews and meta-analyses
indicate that NEC cases needing surgery result in a higher mortality rate, higher costs of care,
longer hospital stays among survivors,(7) and more neurodevelopmental impairment.(8-10) Thus, if
it were possible to somehow prevent NEC cases from progressing to a point where surgery was
needed, outcomes would most likely be better and cost less. However, currently the variables
associated with NEC severity are not well defined, and it is not clear whether such variables
could be modified by clinicians that would lower the prevalence of cases needing surgery.
Risk factors associated with an increased likelihood of developing NEC have been
identified in the literature such as gestational age and birth weight, but few, if any studies have
evaluated the population of NEC (stage II and III) neonates to identify risk factors that increase
the likelihood of developing stage III as compared to stage II NEC. The purpose of our study
was to identify such factors (maternal, neonatal and feeding types in different time periods)
associated with severity of NEC: namely: stage II vs. stage III NEC, severity of laboratory
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values and to factors associated with NEC outcomes including postconceptual age (PCA) in
weeks to full feedings (140 mL/kg/d) post NEC diagnosis, PCA in weeks to discharge, bowel
resection among stage III NEC neonates and death from NEC.

We speculated that factors

associated with NEC severity and outcomes would be identified between the breast fed vs.
formula fed neonate using data existing in a large multihospital healthcare electronic repository
which included 21 hospitals with labor and deliveries.
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OBJECTIVES AND HYPOTHESES

Objective #1: Identify maternal, neonatal and feeding type factors in different time periods for
Bell stage II vs. III NEC

Null hypothesis: There are no differences in factors (maternal, neonatal and feeding
types in different time periods) associated between Bell stage II vs. III NEC for the
neonate receiving mother’s own milk vs. formula.

Alternative hypothesis: The neonate receiving mother’s own milk will have a less severe
form of NEC as compared to the formula fed as measured by maternal, neonatal and
feeding type factors in different time periods.

Objective #2: Identify maternal, neonatal and feeding type factors in different time periods for
laboratory values: highest C-reactive protein (CRP), highest leukocyte count, lowest neutrophil
count, highest ratio of immature neutrophil (metamylocytes and bands) to total neutrophil count
(segmented neutrophils plus bands plus metamylocytes) or I/T ratio, lowest pH, lowest platelet
count and highest mean platelet volume in association with stage II and III NEC for the neonate
receiving mother’s own milk vs. formula.

Null hypothesis: There are no differences in the selected laboratory values (CRP,
leukocyte count, neutrophil count, I/T ratio, pH, platelet count and mean platelet volume)
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within three days of developing stage II and III NEC between the neonate receiving
mother’s own milk vs. formula.
Alternative hypothesis: Selected laboratory values (within three days) will be less severe
for stage II and III NEC for the neonate receiving mother’s own milk vs. formula.

Objective #3: Identify factors (maternal, neonatal and feeding types in different time periods)
associated with NEC outcomes for the neonate receiving mother’s own milk as compared to the
formula fed neonate: post conceptual age (PCA) in weeks to full enteral feedings (140 mL/kg/d),
PCA in weeks to discharge, bowel resection (small intestine and colonic resection) and mortality
from NEC.

Null hypothesis: There are no differences with factors (maternal, neonatal or feeding
types in different feeding periods) for outcomes of post conceptual age (PCA) in weeks to
full feedings after NEC diagnosis and PCA in weeks to discharge between neonates
receiving mother’s own milk vs. formula fed. In addition, there are no differences in
maternal, neonatal or feeding type factors in different time periods for bowel resection
(small intestine and colonic resection) and mortality between neonates receiving mother’s
own milk vs. formula.

Alternative hypothesis: Neonates receiving mother’s own milk who develop stage II and
III NEC have less severe outcomes than formula fed neonates with regards to PCA in
weeks to full feedings (140 mL/kg/d) after NEC diagnosis, PCA in weeks to discharge,
bowel resection (both small and colonic resection) and mortality from NEC.
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LIMITATIONS

We recognize several limitations of our study, foremost of which are those inherent in
retrospective data analyses including susceptibility to error and bias. Other flaws include the
many factors unknown to us because they were not recorded; such as the reasons for ordering the
RBC transfusions and the feeding practices selected, the types of fortifiers used, and why early
mother’s own milk or colostrum was available for some neonates and not for others.
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NECROTIZING ENTEROCOLITIS LITERATURE REVIEW

EPIDEMIOLOGY
Necrotizing enterocolitis rates range from 3 to 7% in all newborn intensive care units
(NICU). (11,12) A database of neonatal hospitalizations found 1.1 cases per 1000 live births (11)
whereas the Canadian neonatal network had a rate of 1.8 per 1000 live births.(12) In the NICHD
Neonatal Network cohort, rates of NEC were inversely related to birth weight, with NEC
affecting 11.5% of infants weighing 401-750 g, 9% of infants 751 to 1000 g, 6% of infants 1001
to 1250 g and 4% infant 1251 to 1500 grams.(13) Thus, the incidence and mortality rates from
NEC are inversely proportional to birth weight and gestational age.(14,15) NEC only occasionally
occurs in the full term infant and is usually associated with predisposing factors such as
congenital heart disease, respiratory disease, or asphyxia.(16) There is no consistent association
between race, sex, and rates of NEC, however, VLBW black infants are at the greatest risk of
death.(11)
Morbidity rates from NEC are high, ranging from 10-30%(11,12) which include
neurodevelopmental impairment, vision and hearing impairment, failure to thrive due to loss of
or dysfunctional bowel, feeding abnormalities, diarrhea, bowel obstruction, or short bowel
syndrome. There are also problems related to long-term use of parenteral nutrition including
catheter related blood stream infections, cholestasis and liver failure.(15) Many cases of NEC can
be managed medically, but roughly 20% to 40% of patients require surgical intervention.(11,12)
Mortality rates from NEC are also high, ranging from 20-30%, with the highest rates
among those requiring surgery.(17) Cases of NEC are usually sporadic, although there have been
reports of outbreaks. These outbreaks occur more commonly in crowded nurseries.(18) It has
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been suggested that the outbreaks may be due to an infectious etiology, however, a specific
organism has never been linked to these episodes. (19)

DIAGNOSIS - Clinical Signs and Symptoms
Necrotizing enterocolitis has an array of presentations including feeding intolerance,
abdominal distention, bilious emesis, temperature instability, lethargy, apnea, bradycardia,
decreased peripheral perfusion, delayed gastric emptying, bloody stools, and respiratory stress.
(15,20)

These symptoms can occur suddenly within a few hours or may be preceded by several

days of feeding intolerance. NEC affects the term infant during the first few days of postnatal
life, at the end of the first week of life for neonates greater than 33 weeks gestational age, during
the first two-and-a-half-weeks in neonates 28-32 weeks and after more than four weeks in
neonates below 28 weeks gestational age.(15)
A systematic description of necrotizing enterocolitis was reported in the literature by Bell
et al (21) in 1978, then, subsequently refined by Walsh et al,(22) and later adopted by the Vermont
Oxford Network.(23) This system assigns necrotizing enterocolitis into three different stages of
severity. Stage I criteria includes highly nonspecific findings of feeding intolerance, mild
abdominal distention, or both, whereas stage II criteria includes the above conditions as well as
radiographic findings of pneumatosis intestinalis or portal venous gas. Stage III criteria includes
those in stage I and II and a pneumoperitoneum.
Nonspecific laboratory abnormalities at NEC diagnosis may include neutropenia,
thrombocytopenia, hyponatremia, hyperglycemia, metabolic acidosis, as well as bacteria or
infectious products isolated from blood, urine, stool or cerebral spinal fluid.(20) Serial C-reactive
protein can be useful in the management of NEC since high levels may predict complications
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such as strictures, abscess, or need for surgery. (24) Early signs of this disease are non specific,
thus sepsis may be suspected before NEC is diagnosed.(15)
The ileum and proximal colon are the most commonly affected sites in NEC although any
segment of the gastrointestinal tract can be involved, including the stomach.(25) Severity can
range from a small localized mucosal necrosis of a bowel segment to necrosis of the entire small
intestine and colon in the most severe cases.

PATHOGENESIS
Etiology
The precise etiology and pathogenesis of NEC is incompletely understood. However,
epidemiologic observations strongly suggest a multifactorial cause.(26) Predisposing factors,
genetic predisposition, intestinal immaturity and an imbalance in microvascular tone
accompanied by a strong likelihood of abnormal microbial colonization in the intestine with a
highly immuno-reactive intestinal mucosa may be involved in the cascade of events leading to
NEC.
Prematurity
Prematurity is the only factor consistently found in epidemiological studies to be an
independent determinant of NEC.(26) Up to 90% of infants with NEC are of low birth weight
(less than or equal to 1500 grams) and the disease is more frequent and severe in those infants
with the earliest post-conceptual age.(27)
Immature Intestinal Motility, Digestion, and Barrier Function
Immature motility, digestion , absorption, immune defenses, barrier function, and
circulatory regulation probably predispose the preterm infant to an increased risk of intestinal
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injury.(28) Intestinal motility is an important factor in clearing antigens presented to the intestinal
mucosal barrier from the gut lumen. Studies on fetal animals and humans suggest that
development of gastrointestinal motility begins in the second trimester and matures in the third
trimester at approximately the eighth month gestation.(29) Premature infants can have immature
intestinal motility patterns as compared with full term infants and induced fetal hypoxia can
reduce postnatal intestinal motility, predisposing the premature infant to NEC.(30) Immature
motility patterns alter normal peristaltic activity and result in overgrowth of anaerobic bacteria in
the small intestine with malabsorption of dietary nutrients.(31) In addition, premature infants
have not yet developed the ability to digest and absorb nutrients, thus contributing to increased
carbohydrate load which may serve as substrate for bacteria.(32)
Gastric acidity provides a first-line defense against bacterial passage into the proximal
intestine. Gastric secretions are limited in the preterm infant, which has been linked to an
increased risk of NEC, particularly among infants receiving histamine receptor antagonists.(13)
Lebenthal and Lee(35) demonstrated that the function of the exocrine pancreas is limited in infants
and may last through the first year of life. Lack of gastric acid and pancreatic secretions and
their resulting proteolysis may adversely affect the intestine by allowing a greater bacterial
and/or antigenic load to develop. Thus, impaired digestion of nutrients with delayed transit time
and bacterial overgrowth could result in intestinal injury with immature host and barrier
defenses.
In addition, if structural or biochemical components of the intestinal epithelial barrier are
not fully developed, bacteria may gain access to deeper tissues and cause inflammation. These
tight junctions between epithelial cells of the intestines create a barrier to fluid and molecules.(34)
A study has shown that intestinal permeability to macromolecules (including immunglobulins,
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proteins, and carbohydrates) is highest in premature infants, especially in those diagnosed with
NEC.(32) Pathogens or toxins may translocate across the leaky intestinal barrier and gain access
to deeper tissues and cause inflammation in the preterm infant.
Goblet cells are specialized enterocytes that secrete mucins, forming a thick mucous
protective layer over the intestinal mucosa in the small and large intestine. This mucus layer
impedes direct microbial-epithelial binding and enhances removal of adherent bacteria.(35)
Goblet cells in the preterm infant are immature which may lead enhance translocation of
bacteria.
Growth factors, growth factor receptors, or their related signal transduction pathways are
aberrant in the immature intestine. Epidermal growth factor (EGF) is a major trophic factor for
the development of the intestine and the EGF receptor has been identified on the basolateral
surface of enterocytes.(36) Expression of EGF receptor involved in intestinal maturation is
decreased in the preterm infant. Recently, human data suggests a link between EGF production
and NEC and using EGF has been suggested to improve epithelial regeneration.(37)
Trefoil factor peptides (TFF1-3) are part of the protective mechanism operating in the
intestinal mucosa and play a fundamental role in epithelial protection and repair.(38) A lack of
trefoil factor expression in response to NEC in the premature gut may contribute to an
insufficient response to reverse mucosal insult observed in NEC.(39) This impaired restitution of
the mucosa may contribute to the cascade of bowel necrosis.
Immature Intestinal Immunity
The immune defense systems are immature and abnormal in the developing neonate. A
possible mechanism for the pathophysiology of NEC is that reduced inflammatory signaling
could allow bacterial overgrowth. Premature infants have macrophages that are defective in
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producing pro-inflammatory cytokines, including tumor necrosis factor-α (TNF-α), interleukin –
1 β, (IL-1β), interleukin-6 (IL-6) and interleukin-12 (IL-12).(40,41) Also, monocytes and T cell
production of the anti-inflammatory cytokines interleukin-10 (IL-10) and TGF-β are
developmentally delayed in the preterm infant.(42) Serum levels of several cytokines and
chemokines that recruit inflammatory cells have been reported to be higher in patients with
necrotizing enterocolitis than in unaffected preterm infants. Interleukin -8, which is produced by
epithelial cells and mediates the migration of neutrophils to the site of inflammation, can cause
necrosis and increased production of acute-phase proteins in the gut.(43,44) Also, newborns have
markedly reduced synthesis of secretory IgA and IgG. These immunoglobulins provide local
intestinal protection against microorganisms, which may infect the mucosa or enter the body
through the gut or respiratory tract.
Hypoxic-Ischemic Injury
It is currently considered unlikely that major perinatal hypoxic-ischemic events
contribute to the pathogenesis of necrotizing enterocolitis.(45-47) However, hypoxia increases
production of vasoconstrictor endothelin-1 and compromises the production of endothelial
derived vasodilator nitric oxide (NO) which could pay a role in the pathogenic cascade that leads
to necrotizing enterocolitis. (48)
Formula Feedings
Enteral feedings have a strong association with NEC. Most NEC cases (90-95%) occur
in infants with initiation/reinitiation of feedings or rapid volume advancement of feedings.(26)
Enteral feedings may disrupt mucosal integrity, blood flow and/or motility and serve as a
substrate for bacteria.(26) Breast fed infants are 10 times less likely to develop NEC than formula
fed infants, suggesting that breast milk contains multiple bioactive factors that influence host
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immunity, inflammation and mucosal protection. Breast milk also increases the diversity of
gastrointestinal bacterial colonization and contains immunomodulatory factors such as secretory
immunoglobulin A, leukocytes, mucin, lysozyme, cytokines, lactoferrin, growth factors (EGF),
and oligosaccharides, many of which are not in commercial formulas.
Alternations in Normal GI Microbiological Flora and Infection
The regions of the intestine that are most often associated with NEC are the ileum and
proximal colon, which have the highest bacterial loads, and abnormal colonization of the
intestinal tract of premature neonates may contribute to NEC. The predominant species of
bacteria found in the GI tract of healthy, term, breast fed infants is Bifidobacteri.(49) In contrast,
species of Staphylococcus, Enterobacter, Enterococcus and Clostridia are the predominant fecal
bacterial species in premature neonates undergoing intensive care, with very little colonization of
Bifidobacteria.(49,50) Clostridium perfringens has been isolated from 40% of infants with
NEC(53) and species of Escherichia and other bacterial, viral and fungal pathogens, including
rotavirus and species of Candida, have been implicated in the etiology of NEC, however no
single pathogen has been identified as a cause of NEC.(25) Premature infants are very
susceptible to intestinal colonization by pathological bacteria and a high likelihood of exposure
to antibiotics on admission to newborn intensive care unit (NICU)(52) which could lead to
pathogenic bacterial growth.
Abnormal expression of pattern recognition receptors may affect the way in which the
intestine in premature infants responds to bacterial colonization. One of the first proinflammatory molecules to cross the intestinal barrier is lipopolysaccharide (LPS), which is a
component of the outer cell wall of gram-negative bacteria that recognizes and binds to toll like
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receptor 4 (TLR-4).(53) The circulating LPSs are increased in neonates with NEC which initiate
inflammatory signaling cascades within the enterocyte.(53)
Vasoactive and Inflammatory Mediators
Nitric oxide (NO), a vasodilator in the gastrointestinal tract mediates inhibitory nerverelated relaxation of intestinal smooth muscle and plays a role in regulating gut mucosal blood
flow, mucosal permeability, and intestinal motility.(54) Nitric oxide maintains intestinal
microvascular integrity by inhibiting platelet aggregation and leukocyte adhesion. Nitric oxide,
in association with peroxynitrite, has anti-microbial properties and play important roles in host
defense against pathogens. Researchers have suggested that NO participates in the pathogenesis
of NEC by directly damaging the enterocyte monolayer by membrane peroxidation and by
disrupting the ability of the mucosa to repair itself. (54) The degree of nitrotyrosine immunostaining (a marker of NO) correlates with apoptosis in enterocytes of the villi of infants with
NEC.(57)
Endothelin -1 is a potent vasoconstrictor agent and is produced in the endothelial cells,
submucosal stroma, and circularis muscularis layers of the gut wall. ET-1 production is
increased by reduced flow, hypoxia and inflammatory cytokines. When excessive amounts of
ET-1 are present, vasoconstriction in the newborn intestine occurs, and recently ET-1 has been
shown to be greater in human preterm intestine with NEC.(55)
Platelet Activating Factor (PAF), an inflammatory and vasoconstrictive mediator, is
synthesized by neutrophils, macrophages, endothelial cells and enterocytes in response to
hypoxia.(24) PAF is rapidly degraded by the enzyme, PAF-acetylhydrolase(56) which is decreased
in the human newborn. This imbalance puts the newborn at risk for an elevated PAF response
before adequate immune stimuli is developed. Formula does not contain PAF-AH like human
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milk, leaving formula fed neonates susceptible to a greater risk for NEC. Neonates with NEC
have high levels of PAF and decreased levels of plasma PAF-AH with levels correlating with
NEC severity.(15, 28)
Pro-inflammatory cytokines are produced in response to inflammatory stimuli that
communicate to the surrounding tissues at the presence of infection or injury. Several proinflammatory cytokines have been implicated in NEC, including tumor necrosis factor-α (TNFα), Interleukin-1β, Interleukin-6, Interleukin-8, Interleukin-12 and Interleukin-18.(43)
Interleukin -8 (IL-8) is triggered in response to various stimuli including LPS, TNF-α,
and IL-1β. Some actions mediated by IL-8 are attraction of neutrophils and basophils to the site
of inflammation, neutrophil activation and migration into tissues and production of acute phase
proteins.(44) Plasma IL-8 levels are elevated in infants with NEC and levels correlate with
clinical severity.(28)
Interleukin-12 (IL-12) synthesis and release is early in response to bacteria and viruses.
IL-12 exerts its effects by binding to IL-12 receptors present on T cells and NK cells.(57) IL-12 is
potentially an important cytokine in the development of NEC.
Interleukin-18 (IL-18) is a proinflammatory cytokine which induces production of TNF-α
and IL-1-β.(60) IL-18 binds to IL-18 receptors present on macrophages, neutrophils, endothelial
cells, smooth muscle cells, and lymphocytes. The risk of NEC has been associated with IL-18
AA genotype.(59)
Interleukin-4 (IL- 4) is an immunoregulatory cytokine produced by Th2 cells, mast cells,
B cells, and stroma cells. IL-4 promotes Th2 type responses and exerts immunosuppressive
effects on macrophages including the suppression of pro-inflammatory cytokine production. (43)
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Studies have shown that very low birth weight infants (less than 1500 grams) with NEC were
less likely to possess the IL-4 receptor alpha-chain as compared to infants without NEC.(59)
Interleukin-10 (IL-10) is a regulatory cytokine in the intestine and is synthesized by the
Th2 cells, monocytes, and B cells.(60) Production of anti-inflammatory mediators such as IL-10
is diminished in the newborn as compared to the adult, with preterm infants synthesizing less
than term infants. Edelson et al.(61) demonstrated increased concentrations of IL-10 with severe
NEC.
Genetics
Studies are currently emerging that investigate the potential importance of specific
polymorphisms for known NEC-associated inflammatory mediators. This genetic variance may
contribute to the individual variances of cytokine responses to inflammatory stimuli. (60) A
family of pathogen recognition receptors has been shown to sense invading bacteria and activate
gene transcription pathways that regulate immune and inflammatory responses. The risk of NEC
has also been associated with the frequency of the IL-18 AA genotype which is significantly
higher in infants with stage III NEC as compared to stages I and II NEC.(60) Another possible
genetic factor is the pro-inflammatory cytokine TNF-α. Pretreatment in animal models with
anti-TNF-α reduced the incidence and severity of NEC. (62,63)
Red Blood Cell Transfusions
An association between the elective transfusion of packed red cells and necrotizing
enterocolitis has been reported.(64) The mechanism by which red cell transfusions are associated
with NEC is unclear but may be related to alterations in intestinal blood flow or hypoxiaischemia events.
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MANAGEMENT
Medical
Medical treatment consists of bowel rest and administration of antibacterials to limit
bacterial invasion and translocation in stage II and III NEC. Initially, neonates with stage II or
III NEC are made NPO (nothing by mouth) and total parenteral nutrition is administered for
nutrition support. A full evaluation for systemic infection for bacterial translocation should be
performed including blood, urine and possibly cerebrospinal fluid cultures. Parenteral antibacterials should be given for a period of 7-14 days in conjunction with bowel rest.(46)
Clinical monitoring along with cardiopulmonary support is routinely performed. Initial
and periodic radiographic evaluations based on clinical status are done to evaluated progression
of the disease. Laboratory values including C-reactive protein (CRP), leukocyte counts,
neutrophils, platelet counts, electrolytes and acid base status should be monitored based on
clinical status and stability of the infant.
Surgical
If an infant does not improve significantly despite medical treatment and if
pneumoperitoneum is present, or if clinical, laboratory and/or radiographic findings worsen,
surgical management is often required. In fact, 20-40% of neonates with NEC require some type
of surgical intervention.(2,11) For many infants with intestinal perforation, laparotomy is
performed with resection of the necrosed portion of the intestine and an ostomy created at the
end proximal to the resected bowel.

PREVENTATIVE MEASURES
Numerous approaches have been proposed for the prevention of necrotizing enterocolitis
which includes withholding enteral feedings, feeding mother’s own expressed breast milk,
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administering probiotic agents or prebiotic agents and administering various growth factors. The
practice of withholding enteral feedings comes from clinical experience and retrospective
reviews suggesting that a rapid increase in feedings increases the likelihood of necrotizing
enterocolitis.(65) However, recent data suggests that withholding feedings may be a dangerous
practice because it leads to the prolonged use of parenteral nutrition which results in intestinal
atrophy, increased permeability and inflammation. Likewise, a delay in feedings may increase
the severity of necrotizing enterocolitis.(65) The following is a review of preventative measures
used with NEC.
Human Milk
Lucas and Cole,(66) in a prospective mulitcenter study, confirmed that NEC was 6 to 10
times more common in exclusively formula-fed infants than in those fed human milk alone and 3
times more common than in those who received formula with human milk. Recently, MeinzenDerr et al.(67) have shown a dose related association of human milk feeding with a reduction of
risk of NEC or death after the first 2 weeks of life among extremely low birth weight infants
(less than or equal to 1000 grams).
The protective effect of breast milk has been correlated with its anti-inflammatory
components (IL10), growth factors (EGF), erythropoietin (Epo), lysozyme, and
immunoglobulins, as well as pre-and probiotics that modulate intestinal microflora composition
to the advantage of the host.(68) The additional presence of an enzyme, platelet activating factoracetyl hydrolase (PAF-AH), activity in human milk may also partly explain the protective effect
of breast milk.(69) PAF-AH degrades PAF and is low in neonates under three weeks of age.(70)
However, breast milk alone does not eliminate NEC completely as cases are reported in neonates
who have been exclusively breast fed.(69) A recent study suggested that the exclusive use of
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human milk plus a human milk-derived fortifier may result in a lower incidence of necrotizing
enterocolitis.(71)
Trophic Feeds
Trophic feedings or small volumes of breast milk or formula may overcome gut atrophy
and inflammatory responses associated with prolonged bowel rest. Trophic feedings improve the
activity of digestive enzymes, enhances the release of digestive hormones and increases
intestinal blood flow and motility in premature infants. It has been shown that early trophic
feedings do not increase susceptibility to developing NEC, however, best feeding strategies for
premature infants are not currently defined.(72)
Standardized Feeding Regimens and Advancement of Feedings
There is a relationship between the rate of feeding advancement and an increased
incidence of NEC.(73) A significant decline of 87% in the incidence of NEC and 29% in the risk
of developing NEC followed implementation of a standardized feeding regimen in the form of
clinical practice guidelines.(74,75)
Probiotics
Prospective randomized trials during the past decade have evaluated the effects of various
probiotics to prevent necrotizing enterocolitis.(76-78) The most recently reported multicenter trial
suggested that using probiotics decreased the incidence of NEC but did not decrease mortality
from NEC. However, there appeared to be a higher incidence of sepsis among infants receiving
probiotics, especially in those with a birth weight of less than 750 grams.(79) Further studies are
needed before routine probiotic prophylaxis is recommended in the premature infant.
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Prebiotics
Another potential preventative strategy is to administer prebiotics, or nutrients that
enhance the growth of potentially beneficial intestinal microbes.(80) Prebiotic agents include
oligosaccharides of inulin, galactose, fructose, lactulose, and other combinations.(81) Although
prebiotics appear to alter the consistency and frequency of stools, their efficacy in preventing
necrotizing enterocolitis remains unclear. Prebiotics enhance the proliferation of endogenous
flora such as Bifidobacteria, and require an initial appropriate colonization of the gut, which may
be lacking in the very low birth weight (less than or equal to 1500 grams) preterm infant.(82)
Epidermal Growth Factor (EGF)
EGF is an important constituent of gastrointestinal secretions and has multiple effects
upon gut epithelial cells including a stimulatory effect on cell proliferation and migration,
induction of mucosal enzyme, trefoil peptide expression, and inhibitory effects on gastric acid
secretion.(37) It has been shown that preterm neonates with NEC have diminished levels of
salivary and serum EGF.(83) The use of prophylaxis EGF could be a possible preventative
measure since EGF receptors are found in gut epithelial cells of preterm neonates with NEC.(84)
However, researchers warrant the clinical use of EGF since there are a variety of problems and
side effects.(85)
Arginine
Intestinal vascular permeability that occurs following an injury allows bacterial
translocation across the intestinal mucosa, setting up the inflammation cascade. Endothelial
nitric oxide (NO) is an anti-inflammatory agent and vasodilator that is involved in the
maintenance of intestinal vascular permeability, mucosal integrity and barrier function.(86) The
plasma levels of the amino acid arginine, a substrate for NO synthase, have been shown to be
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low in neonates with NEC.(87) A study has shown that supplementing neonates with arginine
reduces the incidence of all stages of NEC.(88) However, nitric oxide may not have a significant
protective role for the immature and newborn intestines in ischemia-reperfusion as in the mature
intestine. Whether the beneficial effects of arginine supplementation in the prevention of NEC
are from the synthesis of glutamine and glutamate or to its free radical scavenging action is
unknown. (89,90)
Superoxide Dismutase
Free radicals have been implicated in NEC.(91) Miller et al.(92) have shown that
superoxide dismutase (SOD) prevents damage and attenuates eicosanoid release in a rabbit
model of NEC. Recently, a study demonstrated that intestinal ischemia is associated with a shift
from nitric oxide (NO) to O(2) production, which is NOS-dependent. Potentially greater injury
results from impaired vasodilatation and over-production of reactive oxygen species.(93)
Acidification of Gastric Contents
Preterm neonates are often hypochlorhydric, and enteric, gram-negative bacteria often
colonize their stomachs, especially after gavage feedings.(94) Carrion and Egan (95) have
documented that acidifying the feedings of preterm neonates to a pH low enough to inhibit
gastric bacterial proliferation significantly lowers the risk of NEC.
Polyunsaturated Fatty Acids (PUFA)
Phospholipids are constituents of the mucosal membranes and intestinal surfactant. Their
components, arachidonic acid and choline, are also the substrates for intestinal vasodilatory and
cytoprotective eicosanoids, and the vasodilatory neurotransmitter, acetylcholine. Long chain
PUFAs have been proposed to modulate inflammation and immunity. (96) Carlson et al.(97)
conducted a clinical trial of formula feedings with or without supplementation with PUFA in the
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form of egg phospholipids in preterm neonates. It was noted that the incidence of stage II and III
NEC was significantly less in the supplemented formula group compared with the control
formula group. However, these results need to be interpreted with caution, as the number of
neonates in the supplemented formula group (1/34 vs.15/85) was significantly less. More
recently, a study has shown that PUFA supplemented formula does not alter the risk of NEC or
sepsis.(98)
Enteral Antibiotics
Enteral antibiotics have been used as prophylaxis against NEC in low-birth-weight and
preterm infants given the role of bacterial colonization in the pathogenesis of the illness. A
systematic review and meta-analysis has reported that the administration of prophylactic enteral
antibiotics resulted in a statistically significant reduction in NEC.(99) However, the possible
harmful effects of prophylactic antibiotics, including the development of bacterial resistance,
make it difficult to recommend this strategy for prevention of NEC.
Oral Immunoglobulins
Oral immunoglobulins IgA and IgG have been shown to have an immunoprotective effect
in the gastrointestinal mucosa. A reduction in the incidence of NEC following feeding an oral
IgA-IgG preparation was reported as early as in 1988 by Eibl et al. (100) However, a systematic
review by Foster and Cole (101) identified five trials on oral immunoglobulin for the prevention of
NEC, of which three met the inclusion criteria. The oral administration of IgG or an IgG/IgA
combination did not result in a significant reduction in the incidence of definite NEC. The
researchers concluded that the current evidence does not support the administration of oral
immunoglobulin for the prevention of NEC. (102)
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Erythropoietin
The presence of erythropoietin (Epo) in human milk and the expression of Epo receptors
on intestinal villous enterocytes of neonates suggest that Epo has a role in growth and
development of the gastrointestinal tract.(102) Evidence indicates that the protective effect of
rhEPO may be related to inhibition of NO formation.(103) A recent study demonstrated a role of
Epo in the regulation of intestinal epithelial tight junctions and barrier function and suggests the
possible use of enteral Epo as a therapeutic agent for gut diseases and NEC.(104)
Antenatal Glucocorticoids
Induction of maturation in the developing intestine was first reported by Celano et al.,(105)
Moog (106)and Neu et al. (107) in experimental studies. Other researchers have also shown the
beneficial effects of antenatal glucocorticoid therapy on gastrointestinal maturation and function
including a reduced uptake of macromolecules from the mucosa, decreased colonization with
aerobic bacteria, reduced bacterial translocation to the liver, (108,109) and increased activity of
enzymes like lactase, maltase and sucrase, and Na/K-ATPase.(110) A significant reduction in the
incidence of NEC following antenatal glucocorticoid therapy was subsequently noted in other
studies.(111,112) However, in contrast to previous studies, it was found recently that exposure to
antenatal glucocorticoids was associated with an increased risk for NEC independent of birth
weight. (113)
Other Experimental Agents
A variety of other experimental agents have been studied in the search for an effective
agent for prevention of NEC. These include magnesium,(114) nitroglycerin,(115) clyclosporin and
rapamycin,(116) allopurinol,(117) somatostatin,(118) vitamin A,(119) vitamin E,(120) recombinant
human granulocyte colony stimulating factor,(121) hepatocyte growth factor,(122) sucralfate,(123) L-
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carnitine,(124) interleukin-11, (125,126) interleukin-10,(127) pentoxifylline,(128) pan-caspase
inhibitors,(129) and interferon alpha.(130)

CONCLUSION
Prevention of a multi-factorial illness like NEC is a difficult task because of the poorly
understood pathophysiology of the illness. Since mortality and morbidity related to NEC have
not changed significantly despite the dramatic advances in neonatal and perinatal care, research
in the treatment and prevention of NEC is a priority. Clinical trials of specific “promising”
agents need to be designed carefully and include long-term neurodevelopmental outcomes.
Given that a single effective agent is unlikely in the near future, an approach utilizing a package
of “potentially better practices” (i.e. non aggressive feedings and use of breast milk practices)
seems to be the most appropriate strategy to prevent and minimize NEC.
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APPENDIX B: COMPLETE METHODS
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The proposal for our study was submitted to Brigham Young University and
Intermountain Health Care Institutional Review Boards who required an outline of the study
design, hypotheses and objectives. Students were hired through BYU to assist in collection of
data pertaining to the study. The students were screened for communicable diseases and issued a
temporary badge for identification through Intermountain Health Care. Students also signed
confidential forms at Intermountain Health Care. The study was approved by both the
Intermountain Health Care and Brigham Young University Institutional Review Boards in June
2009, 2010 and then again in June 2011 as a retrospective de-identified study not requiring
individual informed consent. Patients were extracted and identified by the EMPI (electronic
medical patient identification) number. Records of neonates were reviewed if born between
January 1, 2002 and December 31, 2009, admitted to an Intermountain Health Care Newborn
Intensive Care Unit and identified as developing “Bell” stage II or III NEC. Intermountain
Health Care is a not-for-profit-healthcare company owning and operating twenty one hospitals
with labor and delivery services in Utah and Idaho.
Electronic data was extracted from the Help 2 Intermountain Health Care computer
program. Paper records were reviewed at Intermountain Health Care facilities including:


Iron Mountain in Salt Lake City, Utah



Primary Children’s Medical Center in Salt Lake City, Utah



Intermountain Medical Center in Salt Lake City, Utah



Dixie Regional Medical Center in St George, Utah



Valley View Medical Center in Cedar City, Utah



Utah Valley Regional Medical Center in Provo, Utah.
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When NEC was identified, radiographic images, radiographic reports, surgical and
pathology reports, physicians and nurses notes, and electronic records pertaining to NEC were
reviewed. The date of NEC diagnosis was defined as the date the gastric suction tube was
placed. A form was designed to collect pertinent demographic, clinical and surgical data
(Appendix F).
To document the occurrence of NEC we used the criteria originally proposed by Bell and
coworkers,(11) then subsequently modified by Walsh et al., (12) and later adopted by the Vermont
Oxford Network.(13) This definition required the presence of one or more of the following three
clinical signs; 1) bilious gastric aspirate or emesis, 2) abdominal distension, 3) occult or gross
blood in stool (no fissure) AND one or more of the following three radiographic findings: 1)
pneumatosis intestinalis, 2) hepato-biliary gas, 3) pneumoperitoneum. The staging system
assigns necrotizing enterocolitis into three stages of severity. Stage I includes criteria that are
highly nonspecific such as feeding intolerance, abdominal distention, emesis and/or occult or
gross blood in the stool. Stage II NEC criteria are defined as radiographic finding of hepatobilary gas or pneumatosis intestinalis including criteria from stage 1 NEC, and stage III includes
criteria from stage I and II along with pneumoperitoneum.
Maternal, neonatal and feeding type factors at different time periods prior to NEC were
considered in all models for NEC. Maternal risk factors were considered in the models of NEC.
These included:
1)

pregnancy induced hypertension (PIH) and/or HELLP syndrome (group of
symptoms in pregnancy including hemolysis, elevated liver enzymes and low
platelet count)

2)

substance abuse
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3)

smoking during pregnancy, exposure to a smoker in the home

4)

rupture of membranes greater or equal to 18 hours

5)

maternal race

The neonatal risk factors considered in NEC models are listed as follows:
1)

gender

2)

gestational age (in weeks)

3)

birth weight,

4)

Apgar scores at 1 and 5 minutes

5)

birth number (singleton, twin or triplet/quadruplet)

6)

use of histamine receptor antagonist within five days of NEC diagnosis

7)

use of proton pump inhibitors within five days of NEC diagnosis

8)

use of vasopressors (dopamine, dobutamine or milrinone) and nitric oxide (NO)
within five days of NEC diagnosis

9)

classification at birth (small, appropriate or large for gestational age)

10)

hematocrit greater or equal to 65 percent within three days of birth

11)

positive body fluid cultures within seven days of NEC diagnosis

12)

NEC day of life (DOL)

13)

number and volume (mL/kg) red blood cell (RBC) prior to NEC

14)

number and volume (mL/kg) platelet transfusions prior to NEC.

The total number and volume (mL/kg) of RBC and platelet transfusions were recorded
and log transformed (natural log). The lowest pH within three days of NEC was also considered
for models of NEC severity for laboratory blood values, bowel resection and death from NEC.
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All feeding types (including mother’s own milk, fortified mother’s own milk,
pasteurized human milk (PHM), fortified PHM, regular formula, elemental formula, premature
formula and concentrated formula) were recorded to NEC diagnosis and grouped into different
time periods. The different feeding time periods included:
1)

Feedings the first three days of life (DOL)

2)

Feedings the first five DOL

3)

Feedings the first 14 DOL

4)

First five days of feedings (any DOL) and

5)

Feedings to NEC diagnosis.

All feedings in each time period were log transformed for analysis. Breast feedings were
included with mother’s own milk and estimated according to gestational age and day of life
(DOL). Breast feeding amounts for neonates less than 38 gestational age at birth were estimated
as follows:


DOL 1 = 3.5 mL/feeding



DOL 2 - 4 = 5 mL/feeding



DOL 5 = 10 mL/feeding



DOL > 6 = 15 mL/feeding

Estimated breast feeding amounts for neonates greater or equal to 38 gestational age at
birth followed this criteria:


DOL 1 = 3.5 mL/feeding



DOL 2 = 5 mL/feeding



DOL 3 = 12 mL/feeding



DOL 4 = 25 mL/feeding
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DOL 5 = 30 mL/feeding



DOL > 6 = 40 mL/feeding.

The rate of the progression of feedings (the first five days of feedings and first five DOL)
were recorded. This calculation was done by taking the difference in mL of feedings /kg from
one day to the next and averaged the first five DOL and the first five days of feedings.
Feeding types included mother’s own milk, pasteurized human milk(PHM), cow milk
based formula, soy based formula, premature, hydrolyzed formula, fortified mother’s own milk,
using human milk fortifier (HMF), fortified pasteurized human milk (PHM) using HMF,
fortified mother’s own milk using a HMF, fortified PHM using a human milk based fortifier,
premature infant formula, premature discharge formula, concentrated cow milk based formula,
concentrated soy formula, concentrated hydrolyzed formula, and concentrated premature
discharge formula. The feedings in each group were log transformed and percentages were
calculated for analysis.
Feedings were combined into different groups which included:
1)

mother’s own milk plus estimated breast feedings plus PHM

2)

22-24 cal/oz fortified mother’s own milk plus fortified PHM using powdered
HMF

3)

26-30 cal/oz fortified mother’s own milk plus fortified PHM using powdered
HMF

4)

20 cal/oz formula (cow milk based, soy and hydrolyzed)

5)

22-24 cal/oz fortified formulas (cow milk based, soy, and hydrolyzed)

7)

26-30 cal/oz fortified formulas (cow milk based, soy, or hydrolyzed)
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All feeding groups (first three DOL, first five DOL, first 14 DOL, first five feeding days
any DOL, and feedings to diagnosis of NEC) were compared between the two stages of NEC.
Post conceptional age (PCA) in weeks to NEC, PCA to full feedings (140 mL/kg/d) after
NEC diagnosis and PCA to discharge was calculated and recorded.
Stepwise selection models (logistic regression for binary variables) were developed using
SAS (version 9.2, 2008, Cary, NC) which considered the maternal, neonatal, and feeding type
factors in different time periods. Regression models included 1) stage II vs. stage III NEC, 2)
selected laboratory values within three days of NEC diagnosis and 3) outcomes of bowel
resection and death due to NEC. In addition, the lowest pH (arterial or venous within three days
of NEC) was considered in models for the effect on laboratory values, and odds for bowel
resection or death from NEC.
Laboratory values recorded included the highest C-reactive protein, highest leukocyte
count, lowest neutrophil count, highest immature to total neutrophil ratio,(14) lowest pH, lowest
platelet count and highest mean platelet volume. Outcome models for NEC included gestational
age to full feedings after NEC diagnosis (140 mL/kg/d), post conceptual age to discharge, small
and large bowel resection and mortality from NEC.
Pathology and surgical reports were reviewed to determine the anatomic area and length
of bowel resection. Small bowel resections were grouped as follows:


< 20 cm resected



20-75 cm resected



> 75 cm resected.

Colonic resections were grouped as cecum, ascending, transverse, or descending/sigmoid
resections.
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Clinical and descriptive characteristics as well as stepwise regression models are reported
as number (n), percentages (%), least square means (LSM), standard errors (SE), means, r2,
adjusted odds ratios (OR), and 95% confidence intervals (95% CI). P values were set a priori at
α = <0.01.
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APPENDIX C: COMPLETE RESULTS
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A total of 320 neonates were identified with stage > II NEC and born between January 1,
2002 and December 31, 2009 (Figure 1). Ninety six were born at a non-Intermountain
Healthcare hospital and transferred for NEC treatment. These ninety six, as well as four others
born within an Intermountain Healthcare hospital, lacked pre-NEC data essential for analysis and
therefore, were not included in this study. Finally, a total of 220 neonates were included in the
study including 225 NEC episodes (157 stage II and 68 stage III). One patient had three distinct
episodes of NEC stage II, and two patients had one episode of stage II and a subsequent episode
of stage III. Each episode of stage II or III NEC was recorded separately.
Characteristics of those with stage II and stage III NEC are contrasted in Table 1.
Neonates who developed stage III were born at earlier gestational age (P <0.0001) and lower
birth weight (P <0.0001) and with slightly lower 5 minute Apgar score (P = 0.0352). The
diagnosis of NEC occurred on about the same day of life in stage II vs. stage III cases even
though stage II neonates were of slightly older post-conceptual age (PCA) at diagnosis.

No

differences were identified in gender, race, singleton vs. multiple birth number, or any of the
maternal factors considered.
Laboratory values during the three day period before NEC were more likely to abnormal
among those who developed stage III (Table 2). Specifically, the group that developed stage III
had a higher CRP, I/T neutrophil ratio, and MPV, and a lower pH and platelet count. However,
neutropenia and leukocytosis were not more common in one group than the other. Several
laboratory values were missing during this time period including a total of 31 C-reactive protein
values, seven leukocyte counts, seven I/T neutrophil ratios, eleven total neutrophil counts, 82
pHs, eight platelet counts and nineteen mean platelet volumes.
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Red blood cell (RBC) and platelet transfusions prior to NEC were much more common
among those who had stage III (Tables 3 and 4). The use of vasopressors and/or nitric oxide
(NO), within five days of developing NEC, were more common in those who went on to stage
III; and death and death ascribed to NEC were also much more common in this group (Table 5).

Model for Stage II vs. Stage III NEC
Factors identified in regression analysis predicting a greater likelihood of stage III vs. stage II
NEC were 1) a greater volume (mL/kg) of RBC transfusions (OR 2.413, {CI 1.854 to 3.107}
P<0.0001), and 2) a greater volume of pasteurized human milk prior to NEC development (OR
1.316, {CI 1.071 to 1.617}, P = 0.0089). Factors that predicted a lower likelihood of stage III
included 1) earlier feedings with mother’s own milk (colostrum – first five days of feedings)
((OR 0.802, {CI 0.669 to 0.961}, P = 0.0170). and 2) an earlier DOL to NEC diagnosis (OR
0.937, {CI 0.906 to 0.968}, P <0.0001)

Models for Laboratory Values
Laboratory values within each stage of NEC included the highest CRP, highest leukocyte
count, highest immature neutrophil to total neutrophil ratio, lowest neutrophil count, lowest pH,
lowest platelets, and highest mean platelet volume within three days of NEC.
Two factors predicted a greater likelihood of a high CRP within stage II NEC including: 1) a
low pH (P <0.0001) and 2) small for gestational age (SGA) (P= 0.0076). r2 = 0.328. A low pH
(P= 0.0003) was identified as the only predictor for a high CRP within stage III NEC. r2 =
0.249.
No significant predictors were identified for a high leukocyte count within stage II NEC. We
identified seven factors that predicted a greater likelihood of high leukocytes within stage III
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NEC. These included 1) a lower gestational age (P <0.0001); 2) Platelet transfusions (P =
0.0027); 3) fortified mother’s own milk and PHM (log unit) to DOL 14 (P<0.0001); 4) less
mother’s own milk and PHM (log unit) to diagnosis of NEC (P <0.0001); 5) PHM (log unit) to
DOL five (P = 0.0007); percent mother’s own milk with PHM (log unit) to NEC diagnosis (P =
0.0013); and 6) Less fortified formula (log unit) to NEC diagnosis (P = 0.0039). r2 = 0.762.
Two factors predicted a greater likelihood of a high I/T neutrophil ratio within stage II NEC
including 1) a low pH (P <0.0001) and 2) a higher percent of PHM the first five DOL (P =
0.0048). r2 = 0.354. Four factors that predicted a greater likelihood of a high immature
neutrophil to total neutrophil ratio (I/T ratio) within stage III NEC. These included 1) a lower use
of proton pump inhibitors (P <0.0001) or histamine receptors antagonists (P = 0.0021); 2) fewer
red blood cell transfusions (P = 0.0043); 3) total feeding (log unit) to NEC diagnosis (P=0.0003);
and 4) lower percent of early mother’s own milk the first three DOL (P = 0.0056). r2 = 0.522.
A single predictor for a low neutrophil count within stage II was a lower birth weight
(P=0.0004). r2 = 0.235. For stage III NEC, total feedings (log unit) to NEC diagnosis was the
only predictor for a low neutrophil count (P= 0.0002). r2 = 0.25.
Four factors predicted a greater likelihood of a low pH within stage II including 1) higher
volume (mL/kg) of RBC transfusions (P = 0.0086); 2) positive cultures prior to developing NEC
(P = 0.0008); 3) a lower birth weight (P = 0.082) and 4) lower amounts of fortified (22-24
cal/oz) formula (log unit) to NEC diagnosis (P = 0.0027). r2 = 0.461. Two factors predicted a
greater likelihood of a low pH within stage III NEC included 1) lower amounts of fortified (2224 cal/oz) formula (log unit) to NEC diagnosis (P <0.0001) and 2) fortified )22-30 cal/oz)
formula (log unit) to NEC diagnosis (P <0.0001). r2 = 0.312.
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Four factors predicted a greater likelihood of a lower platelet count within stage II NEC.
These included 1) a low pH (P <0.0001); 2) lower percent of early mother’s own milk the first
five DOL (P = 0.0002); 3) fewer total feedings (log unit) to NEC diagnosis (P = 0.0004); and 4)
higher percent mother’s own milk combined with PHM the first 14 DOL (P= 0.0019). r2 =
0.475. No significant predictors were identified for a low platelet counts within stage III NEC.
Two factors predicted a high mean platelet volume within stage II NEC including: 1)
lower percent of early mother’s own milk for the first five DOL (P = 0.0083) and 2) lower
percent of fortified (22-24 cal/oz) mother’s own milk combined with fortified (22-24 cal/oz)
PHM to the NEC diagnosis (P = 0.0021). r2 = 0.386. Four factors predicted a high mean platelet
volume within stage III NEC including 1) use of histamine receptor antagonists (P <0.0001); 2)
lower maternal substance abuse (P = 0.0030); 3) lower total feedings (log unit) to DOL 14 (P =
0.0052); and 4) mother’s own milk (log unit) to NEC diagnosis (P = 0.0083). r2 = 0.49.
We concluded that laboratory values did not show any significant factors that were
practically significant or meaningful based on the selected maternal, neonatal, or feeding type
factors in different time periods studied.

Models for Post Conceptual Age in Weeks to Full Feedings post NEC
Four factors were identified that predicted a greater likelihood for earlier post conceptual age
(PCA) in weeks to full feedings (140 mL/kg/d) within stage II NEC including 1) a lower
gestational age (P <0.0001); 2) less total feeding (log unit) to NEC diagnosis (P = 0.0002); 3)
percent of early mother’s own milk the first five DOL (P = 0.0020); and 4) lower total feedings
(log unit) to DOL 14 (P = 0.0047). r2 = 0.755. Four factors predicted a greater likelihood for
earlier post PCA to full feedings (140 mL/kg/d) within stage III NEC including: 1) a lower
gestational age (P = 0.0002); 2) no maternal substance abuse (P = 0.0023); 3) less percent PHM
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to NEC diagnosis (P = 0.0006); and 4) a lower percent of 20 cal/oz formula (cow milk based or
soy) the first five feeding days (any DOL) (P = 0.0056). r2 = 0.683.
We concluded that PCA to full feedings (140 mL/kg/d) in both stage, did not show any
practically significant findings that were meaningful based on the selected maternal, neonatal, or
feeding type factors in different time periods studied.

Model for Post Conceptual Age in Weeks to Discharge
Seven factors predicted a lower PCA in weeks to discharge within stage III including: 1)
maternal race (P<0.0001) (specifically: hispanics were 45.1 PCA in weeks, whites were 45.6
PCA in weeks and other races were 58.6 PCA in weeks), 2) number of RBC transfusions (P =
0.0009), 3) higher gestational age (P = 0.002), 4) PHM (log unit) the first five feeding days, any
DOL (P = 0.0003), 5) less early mother’s own milk (log unit) the first three DOL (P = 0.0013),
6) the percent early mother’s own milk the first five DOL (P = 0.0049), and 7) less PHM (log
unit) the first three DOL (P = 0.0073). r2 = 0.697.
We concluded that regression models for PCA to discharge did not show any practically
significant findings that were meaningful based on the selected maternal, neonatal, or feeding
type factors in different time periods studied.

Models for Bowel Resection
A regression model for small bowel resection among stage III NEC demonstrated that
those with an intact small bowel were more likely to have received mothers own milk combined
with PHM to NEC diagnosis (OR 0.936, {CI 0.885 to 0.989}, P = 0.0194). A regression model
for large bowel resection did not demonstrate any significant maternal, neonatal or feeding type
factors influencing colonic resection.
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All bowel resection (small or large bowel) comparing mild resection vs. moderate/severe
resection plus the expired neonates for stage III NEC showed no predicting factors: maternal,
neonatal or feeding types in different time periods were significant.

Model for Death from NEC
Five factors significantly predicted the likelihood of death from NEC among those that
had stage III disease included 1) a low pH (OR 2.212, {CI 1.27 to 3.853}, P = 0.0050), 2) the
absence of PIH or HELLP syndrome (OR 0.018, {CI 0.001 to 0.273}, P = 0.0038), 3) less early
mother’s own milk (log unit) for five days (any DOL) (OR 0.961, {CI 0.937 to 0.986}, P =
0.0025), 4) less total feedings (log unit) to DOL 14, (OR 0.618, {CI 0.431 to 0.885}, P =
0.0087), and 5) less percent of formula to DOL 14 (OR 0.965, {CI 0.937 to 0.993}, P = 0.0151).
A regression analysis demonstrated that gestational age increased by 0.08 weeks for each
percent of formula the first 14 DOL (P <0.0001) and gestational age also increased by 0.37
weeks for every log of total feedings to DOL 14 (P = 0.1228). Thus, formula and total feedings
to DOL 14 were more common among the larger gestational age neonates.
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Figure 1 Diagramatic display of the subjects studied
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Table 1 Characteristics of 220 neonates and 225 episodes of stage > II NEC
Stage II n = 157
Stage III n = 68
← n (%) →
29 (18.5)
13 (19.1)

Maternal Factors
PIH and/or HELLP
syndrome
Smoker
19 (12.1)
Smoker in the home
24 (15.3)
Substance abuse
9 (5.7)
Rupture membranes >18 hrs
32 (20.4)
Unknown
6 (3.8)
Fetal/ Neonatal Factors
Gender: Male
76 (48.4)
Female
81 (51.6)
Race: White
122 (77.7)
Black
5 (3.2)
Hispanic
21 (13.4)
Other
9 (5.7)
Small for Gestational Age
21 (13.4)
(SGA)
Singleton
115 (73.3)
Twin
39 (24.8)
Triplet or Quadruplet
3 (1.9)
Hematocrit > 65 percent
4 (2.6)
Proton Pump Inhibitors or
99 (63.1)
Histamine receptor
antagonists within 5 days of
NEC
Least Square Means (95% Confidence Intervals)
Gestational age (weeks)
32.7 (32.0 - 33.3)
Birth weight
(grams)
1891 (1774-2008)
Apgar score: 1 minute
5.95 (5.55 – 6.35)
Apgar score: 5 minutes
7.83 (7.58 – 8.09)
PCA at NEC diagnosis
35.5 (34.9 - 36.1)
NEC day of life
19.9 (17.1 - 22.7)
PCA to full feedings (140
38.55 (37.8 - 39.3)
mL/kg/d) after NEC
diagnosis
Discharge PCA
40.9 (40.1 - 41.8)

0.909

7
8
4
8
4

(10.3)
(11.8)
(5.9)
(11.8)
(5.9)

0.697
0.487
0.965
0.260

38
30
47
1
14
6
10

(55.9)
(44.1)
(69.1)
(1.5)
(20.6)
(8.8)
(14.7)

0.303

50
15
3
0
49

(73.5)
(22.1)
(4.4)
(0.0)
(72.1)

0.531

30.0
1371
5.34
7.33
32.8
20.9
41.3

(29.0 - 30.9)
(1193 – 1549)
(4.73 - 5.96)
(6.93 - 7.72)
(31.9 - 33.8)
(15.8 - 24.4)
(39.8 - 42.7)

46.5 (44.9 - 48.1)

PIH - pregnancy induced hypertension
HELLP syndrome - a group of symptoms including hemolysis, elevated
liver enzymes, and low platelet count
PCA - Post Conceptual Age
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P-value

0.176

0.790

0.184
0.191

<0.0001
<0.0001
0.107
0.035
<0.0001
0.946
0.001

<0.0001

Table 2 Laboratory values three days preceding 225 episodes of stage > II NEC
Stage II NEC n= 157
Highest C-Reactive
Protein (CRP) mg/dL
Highest Leukocyte
count 103/µL
Highest I/T neutrophil
ratio**
Lowest Neutrophil
Count 103/µL
Lowest pH (arterial or
venous)
Lowest Platelet Count
103/µL
Highest Mean Platelet
Volume (MPV) fL

Stage III NEC n = 68

P-value

Means
2.08

s.d. *
4.09

Means
5.26

s.d.
5.35

<0.0001

13.34

5.45

16.01

11.98

0.029

0.26

0.87

0.55

0.29

0.001

4.60

3.29

4.99

6.59

0.570

7.32

0.09

7.15

0.13

<0.0001

339.3

136.0

175.7

128.7

<0.0001

9.50

1.47

10.65

1.69

<0.0001

* Standard deviation
**Ratio of immature neutrophils (metamylocytes and bands) to total neutrophils
(segmented neutrophils plus bands plus metamyeocytes)
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Table 3 Feeding types preceding 225 episodes of stage > II NEC

Total volume
Mother’s own milk (MOM)
% MOM
Pasteurized human milk (PHM)
MOM + PHM
% MOM and PHM
22-24 cal/oz MOM using powdered
human milk fortifier (HMF)
22-24 cal/oz PHM using powdered
HMF
22-30 cal/oz MOM + PHM using
powdered HMF
% 22-30 cal/oz MOM + PHM using
powdered HMF
20 cal/oz cow milk based and soy
formula
22-24 cal/oz cow milk based and soy
formula
20 cal/oz Hydrolyzed formula
22-24 cal/oz Hydrolyzed formula
20 cal/oz cow milk based, soy and
hydrolyzed formula
% 20 cal/oz cow milk based, soy, and
hydrolyzed formula
22-30 cal/oz cow milk based, soy and
hydrolyzed formula
% 22-30 cal/oz cow milk based, soy,
and hydrolyzed formula

mL
mL
mL
mL

Stage II n= 157
LSM (95% CI)*
1252 (953 - 1644)
164.3 (113.0 - 238.8)
31.7 (26.9 – 36.5)
1.5 (1.1 - 1.9)
146.8 (98.8 - 218.2)
29.7 (24.9 – 34.5)
33.4 (19.5 - 56.9)

Stage III n = 68
LSM (95% CI)
527 (362 - 828)
90.1 (51.0 - 159.1)
37.6 (30.3 - 45.0)
2.7 (1.9 - 4.1)
112.9 (62.1 - 205.3)
39.7 (32.4 - 47.0)
19.6 (8.7 – 44.2)

P-value

1.3 (1.0 – 1.7)

2.1 (1.5 - 3.1)

0.0376

37.5 (21.6 - 65.2)

25.95 (11.22 - 60.0)

0.4705

26.4 (21.4 - 31.4)

25.4 (17.9 - 32.9)

0.8278

22.8 (14.6 - 35.7)

8.7 (4.4 – 17.2)

0.0210

7.2 (4.7 - 11.2)

4.5 (2.3 - 8.9)

0.2540

2.1 (1.6 – 2.9)
1.4 (1.1 – 1.7)
33.3 (20.8 - 53.1)

1.7 (1.0 - 2.7)
1.2 (0.9 - 1.6)
10.6 (5.2 – 21.6)

0.4163
0.4525
0.0111

26.3 (21.0 - 31.5)

19.8 (11.7 – 27.9)

0.1877

9.7 (6.1 - 15.5)

6.2 (3.0 - 12.7)

0.3045

11.5 (8.1 - 15.0)

9.3 (4.0 - 14.5)

0.4724

0.0012
0.0834
0.1823
0.0072
0.4705
0.0254
0.2841

mL
mL
mL

mL
mL
mL
mL
mL

mL

*Least square means (unlogged) and 95% confidence intervals
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Table 4 Red blood cell (RBC) and platelet transfusions preceding 225 episodes of stage > II NEC

RBC Transfusions
Platelet
Transfusions

Stage II NEC n = 157
LSM (95% CI)*
1.8 (1.6 – 2.1)
1.1 (1.0 – 1.3)

Stage III NEC n = 68
LSM (95% CI)
4.0 (3.2 – 4.9)
1.7 (1.5 – 2.0)

*Least square means (95% confidence intervals)
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P-value
<0.0001
<0.0001

Table 5 Morbidity and mortality of 220 neonates with 225 episodes of stage > II NEC
Stage II NEC
n = 157
← n (%)
Positive cultures (within
7 days before NEC)
Blood
Urine
None
Positive cultures (within
7 days before and after
NEC)
Blood
Urine
Multiple
None
Peritoneal Cultures
(within 7 days after
NEC)
Vasopressors/ nitric
oxide (within 5 days
before and after NEC)
Dopamine
Dobutamine
Milirone
Nitric Oxide
Small bowel resection
None
<20 cm
20-75 cm
>75 cm
Died before surgery
Colonic resection
None
1 section
2 sections
3 sections
Died before surgery
Total Mortality
Mortality from NEC

Stage III NEC
n= 68
→

P-value

0.0321
7 (4.5)
1 (0.6)
149 (94.9)

7 (10.3)
3 (4.4)
58 (85.3)
0.0001

27
6
2
122

(17.2)
(3.8)
(1.3)
(77.7)

23
3
7
35

(33.8)
(4.4)
(10.3)
(51.5)

0 (0)

10 (14.7)

<0.0001

7
1
2
1

(4.5)
(0.6)
(1.3)
(0.6)

48
14
5
3

(70.6)
(20.6)
(7.4)
(4.4)

<0.0001
<0.0001
0.0159
0.0491

157 (100)

6
27
17
13
5

(8.5)
(39.7)
(25.0)
(19.1)
(7.4)

<0.0001

157 (100)

22
7
12
22
5
28
24

(32.4)
(10.3)
(17.7)
(32.4)
(7.4)
(41.2)
(35.3)

<0.0001

5
0

(3.2)
(0)
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<0.0001
<0.0001

Table 6 Feeding types the first 3 days of life preceding 225 episodes of stage > II NEC
Variable
Early mother’s own milk (MOM) mL
%Early MOM
Pasteurized human milk (PHM) mL
20 cal/oz cow milk based and soy
based formula
mL
% 20 cal/oz cow milk based and soy
based formula

Stage II NEC n = 157
LSM (95% CI)*
3.3 (2.6 - 4.20)
20.5 (15.2 – 25.8)
1.3 (1.1 - 1.4)
6.7 (4.8 - 9.3)

Stage III NEC n = 68
LSM (95% CI)
2.1 ( 1.5 - 3.0)
15.8 ( 7.8 - 23.8)
1.4 ( 1.2 - 1.7)
3.5 ( 2.1 - 5.8)

P-value

38.2 (31.3 – 45.0)

26.3 (15.8 – 36.8)

0.0631

0.0489
0.3329
0.3480
0.0383

*Least square means and 95% confidence intervals
Table 7 Feeding types the first 5 days of life preceding 225 episodes of stage > II NEC
Variable
Early mother’s own milk (MOM) mL
% Early MOM
Pasteurized human milk (PHM) mL
22-24 cal/oz early MOM using
powdered human milk fortifier (HMF)
mL
20 cal/oz cow milk based and soy
based formula
mL
% 20 cal/oz cow milk base and soy
based formula

Stage II NEC n = 157
LSM (95% CI)*
12.6 (8.9 - 17.7)
36.4 (30.0 – 42.9)
1.3 (1.1 - 1.5)
1.1 (1.0 - 1.2)

Stage III NEC n=68
LSM (95% CI)
6.1 (3.6 - 10.3)
35.5 (25.8 – 45.2)
1.5 (1.2 - 1.8)
1.0 (0.9 - 1.1)

P-value

11.5 (7.8 - 17.1)

4.5 (2.5 - 8.3)

0.0116

33.8 (27.5 – 40.0)

22.6 (13.1 – 32.2)

0.0564

*Least square means and 95% confidence intervals
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0.0234
0.8762
0.4288
0.3523

Table 8 Feeding types the first 14 days of life preceding 225 episodes of stage > II NEC
Variable
Total volume
mL
Mother’s own milk (MOM)
mL
% MOM
Pasteurized human milk (PHM)
mL
MM + PHM
mL
% MM + PHM
22-24 cal/oz MOM using powdered
human milk fortifier (HMF)
mL
22-24 cal/oz PHM using powdered
HMF
mL
22-30 cal/oz MOM + PHM using
powdered HMF
mL
% 22-30 cal/oz MOM + PHM using
powdered HMF
20 cal/oz cow milk based or soy based
formula
mL
22-24 cal/oz cow milk based or soy
based formula
mL
20 cal/oz hydrolyzed formula
mL
22-24 cal/oz hydrolyzed formula mL
20 cal/oz cow milk based, soy and
hydrolyzed formula
mL
% All 20 cal /oz cow milk based, soy,
and hydrolyzed
mL
22-30 cal/oz combined fortified cow
milk based, soy, and hydrolyzed
formula
mL
% combined 22-30 cal/oz cow milk
based, soy, and hydrolyzed formula

Stage II NEC n= 157
LSM (95% CI)*
369 (258 – 529)
78.9 (53.2 – 116.7)
44.5 (38.5 - 50.6)
1.4 (1.2 – 1.8)
71.4 (47.6 – 107.2)
40.0 (33.8 - 45.9)
11.3 (7.1 – 17.8)

Stage III NEC n = 68
LSM (95% CI)
136 (79 – 235)
38.5 (20.7 - 67.9)
53.0 (43.7 - 62.3)
1.8 (1.3 – 2.5)
45.4 (24.4 - 84.1)
51.2 (42.1 - 60.4)
4.5 (2.2 – 9.0)

P-value
0.0030
0.0406
0.1361
0.2197
0.2195
0.0410
0.0307

1.2 (1.0 – 1.4)

1.4 (1.1 – 1.8)

0.3128

11.6 (7.3 – 18.6)

5.3 (2.6 – 10.8)

0.0709

17.3 (13.3 – 21.3)

13.4 (7.3 – 19.5)

0.2959

12.2 (7.9 – 18.8)

5.3 (2.8 – 10.3)

0.0388

3.2 (2.3 - 4.5)

1.8 (1.1 – 3.0)

0.0559

1.2 (0.9 – 1.7)
1.0 (0.8 – 1.2)
6.2 (3.2 – 12.0)

0.3443
0.1938
0.0040

1.5 (1.2 - 1.8)
1.2 (1.0 - 1.3)
15.9 (10.3 – 24.7)
23.5 (18.2 – 28.8)
3.6 (2.6 – 5.2)
7.3 (4.41 – 10.1)

*Least square means and 95% confidence intervals
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18.2 (10.1 –
26.2)
1.8 (1.0 - 3.0)

4.1 (-0.3 - 8.4)

0.2745
0.0277

0.2278

Table 9 Feeding types the first 5 feeding days (any day of life)
preceding 225 episodes of stage > II NEC
Variable
Mother’s own milk (MOM)
mL
% MOM
Pasteurized human milk (PHM) mL
22-24 cal/oz MOM using powdered
human milk fortifier (HMF)
mL
20 cal/oz cow milk based and soy
formula
mL
% 20 cal/oz cow milk based formula

Stage II NEC n = 157
LSM (95% CI)*
73.8 (53.4- 102.1)
60.6 (54.3 – 66.9)
1.3 (1.1 – 1.6)
1.3 (1.1 – 1.5)

Stage III NEC n= 68
LSM (95% CI)
32.5 (19.9 – 53.1)
61.9 (52.4 – 71.5)
1.7 (1.3 – 2.1)
1.1 (0.9 – 1.40)

P-value
0.0063
0.8228
0.1854
0.4115

18.7 (12.3 – 28.5)

6.6 (3.5 – 12.5)

0.0079

32.9 (26.8 – 39.1)

25.0 (15.6 - 34.3)

0.1624

*Least square means and 95% confidence intervals
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Table 10 Feeding types preceding 225 episodes of stage > II NEC
Variable

Stage III NEC n = 68
LSM (95% CI)
527 (362 - 828)
90.1 (51.0 - 159.1)
37.6 (30.3 - 45.0)
2.7 (1.9 - 4.1)
112.9 (62.1 - 205.3)
39.7 (32.4 - 47.0)
19.6 (8.7 – 44.2)

P-value

1.3 (1.0 – 1.7)

2.1 (1.5 - 3.1)

0.0376

37.5 (21.6 - 65.2)

25.95 (11.22 - 60.0)

0.4705

26.4 (21.4 - 31.4)

25.4 (17.9 - 32.9)

0.8278

22.8 (14.6 - 35.7)

8.7 (4.4 – 17.2)

0.0210

7.2 (4.7 - 11.2)

4.5 (2.3 - 8.9)

0.2540

2.1 (1.6 – 2.9)
1.4 (1.1 – 1.7)
33.3 (20.8 - 53.1)

1.7 (1.0 - 2.7)
1.2 (0.9 - 1.6)
10.6 (5.2 – 21.6)

0.4163
0.4525
0.0111

% 20 cal/oz cow milk based, soy, and
hydrolyzed formula
mL
22-30 cal/oz cow milk based, soy and
hydrolyzed formula
mL

26.3 (21.0 - 31.5)

19.8 (11.7 – 27.9)

0.1877

9.7 (6.1 - 15.5)

6.2 (3.0 - 12.7)

0.3045

% 22-30 cal/oz fortified cow milk based,
soy, and hydrolyzed formula

11.5 (8.1 - 15.0)

9.3 (4.0 - 14.5)

0.4724

Total volume
mL
Mother’s own milk (MOM)
mL
% MOM
Pasteurized human milk (PHM)
mL
MOM + PHM
mL
% MOM + PHM
22-24 cal/oz MOM using powdered
human milk fortifier (HMF)
mL
22-24 cal/oz PHM using powdered
HMF
mL
22-30 cal/oz MOM+PHM using
powdered HMF
mL
% 22-30 cal/oz MOM + PHM using
powdered HMF
20 cal/oz cow milk based and soy
formula
mL
22-24 cal/oz cow milk based and soy
formula
mL
20 cal/oz hydrolyzed formula
mL
22-24 cal/oz hydrolyzed formula mL
20 cal/oz cow milk based, soy, and
hydrolyzed formula
mL

Stage II NEC n= 157
LSM (95% CI)*
1252 (953 - 1644)
164.3 (113.0 - 238.8)
31.7 (26.9 – 36.5)
1.5 (1.1 - 1.9)
146.8 (98.8 - 218.2)
29.7 (24.9 – 34.5)
33.4 (19.5 - 56.9)

*Least square means and 95% confidence intervals
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0.0012
0.0834
0.1823
0.0072
0.4705
0.0254
0.2841

APPENDIX D: COMPLETE DISCUSSION
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The most significant associations with severe NEC we identified were earlier gestational
age, lower birth weight and larger volumes of RBC transfusions administered prior to NEC
diagnosis. The most significant protective factor from severe NEC we identified was early
mother’s own milk feedings. However, this protective effect was not observed for pasteurized
human milk. However, no cause and effect are claimed with the association of RBC transfusions
and severity of NEC.
Many reports have identified an association of RBC transfusions and the development of
NEC

(1-2)

but this is the first report demonstrating the association between RBC transfusions and

NEC severity. A recent study indicated that 1) 25-30 percent of NEC cases followed a RBC
transfusion generally within 6 to 24 hours, 2) neonates with transfusion-associated NEC are
generally born at earlier gestational age than those with NEC and no antecedent transfusion, and
3)neonates with transfusion-associated NEC have generally had one or more previous RBC
transfusions before the one that precipitates NEC.(3) Our study demonstrated an association of
RBC transfusions with the severity of NEC.
As the log unit of pasteurized human milk increased prior to NEC diagnosis, there was a
32 percent increased likelihood for stage III. Distinct differences exist between pasteurized
human milk and fresh maternal milk. The process of pasteurization (Holder method = 62.5
degrees C for 30 minutes) inactivates cellular components of milk, including T cell and B cells,
macrophages, and neutrophils.(4-6) Concentration of immunoglobulins A and G are also
significantly reduced, as are lactoferrin, (6-7) lysozymes, (8) and erythropoientin. (9-10) Some
growth factors have been reported to be reduced by pasteurization, including insulin-like growth
factor-1 and insulin-like factor-2,(11) whereas others, like epidermal-like growth factor (EGF)
and transforming growth factor-beta appear capable of withstanding heat treatment.(12) As human
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milk banking increases, it is critical to understand the effect of pasteurization on immunological
components and to improve processing techniques to better preserve these components.
In contrast, early mother’s own milk or colostrum (first five days of feedings) was
associated with a reduction in odds for severe NEC (stage III). Colostrum as compared to
mature maternal milk has many unique features including higher concentrations of secretory
IgA, lactoferrin, anti-inflammatory cytokines, oligosaccharides, soluble CD-14 which binds to
whole bacteria and bacterial cell wall components, and antioxidants.(13-15) Moreover, mothers of
the most preterm infants produce colostrum with even higher concentrations of many such
factors compared with mothers of term infants.(16-18)
The observation that colostrum may decrease NEC severity, which generally occurs some
three weeks later, is consistent with the recent observations from Gonzalez-Reivera et al.(19) that
NEC may be a consequence of events occurring soon after birth. We suggest that feeding
colostrum (or lack there of) could be such an event.
Regression models for selected laboratory blood value (highest CRP, lowest leukocytes,
highest I/T ratio, lowest neutrophil count, lowest pH, lowest platelet and highest mean platelet
volume) demonstrated no meaningful predictors in the severity of NEC. Thus, we concluded
that mother’s own milk feedings vs. formula did not make any significant difference in the
severity of NEC as examined by laboratory values.
We found that mother’s own milk in combination with PHM had a protective effect on small
bowel resection, whereas pasteurized human milk alone did not. However, the model for large
bowel resection and severity of small and large bowel resection showed not maternal, neonatal or
feeding type factors that predicted outcome.
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Post conceptual age to full feedings (140 mL/kg/d) and PCA to discharge showed
multiple predictors, but none that were consistent. Thus, we concluded that there were no
feeding groups (mother’s own milk, PHM or formula) that made a significant difference in
achieving an earlier post conceptual age to full feedings post NEC or to discharge.
We also focused on factors associated with death from NEC and found that early
colostrum feedings for five days decreased the odds of mortality. Recently, Meinzen-Derr et
al.(20) also demonstrated an association between human milk feedings gven the first two weeks
and reduction in death from NEC. Other factors that decreased the odds of mortality were 1)
total feedings to DOL 14 and 2) formula the first 14 DOL. A regression model for gestational
age and formula the first 14 DOL indicated that as gestational age increased in weeks, there was
an increase in formula use and total feedings given. We suspect that the decreased risk of death
by the use of formula and total feedings to DOL 14 was attributed to the larger gestational age
neonate who was thus less likely to die from NEC.
We recognize several limitations of our study, foremost of which are those inherent in
retrospective data analyses including susceptibility to error and bias. Other flaws include the
many factors unknown to us because they were not recorded, namely, the reasons or timing of
RBC transfusions, different feeding practices, different types of fortifiers used, and why
colostrum was available for some neonates and not for others.
In conclusion, we sought to find associations with sever NEC using data from a
multicentered healthcare database. Indeed we observed that neonates who received more RBC
transfusions and less colostrum were more likely to have stage III disease. It is not clear whether
successful programs to encourage early colostrum feedings would decrease the prevalence of
stage III NEC in actual practice. Certainly any salutary effect of such practice changes could
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have important beneficial effects for neonates, their families and society. Continued ongoing
and future investigative efforts are necessary due to high human and economic costs of stage III
NEC disease.
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APPENDIX F: MATERIALS
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EMPI#

 ANTEPARTUM HX: PIH

Smoker during pregnancy
Smoker in home

HELLP syndrome



Pt#

BIRTH/ TRANSPORT Hx: Facility
Birth date

Methamphetamines
Cocaine

Discharged

LOS (d)

Rupture of membranes:
________hrs

Encounter#

Birthplace

Admit date
Admit date

Hct day 1-3:



PCA at discharge _________ weeks

DEMOGRAPHICS:
GA
BW

Classification Birth number
SGA

Mom’s Race: White

AGA

LGA

Apgar Scores
1 min

10 min

1st 14 DOL or to NEC___________mls

 Gastric
Suction
Tube Placement

Feedings
Total amt
% of total

Symptoms/ Findings Abdominal distension

________ Penumatosis intestinalis
________ Portal venous gas
________ Pneumoperitoneum

Bloody stools
Bilious emesis/ residuals

CULTURES (Blood, urine, CSF) 7 d prior/post gastric suction tube placement
Date

5 min

Hispanic Black Other:

Date



Gender
Male
Female

Site

From ________ to _____

Results

MEDICATIONS:

5 days prior/ post gastric suction tube placement; From: ___________ to ________
H2 receptor antagonists Proton Pump Inhibitors
Dopamine
Nitric Oxide
Pepcid (Famotidine)
Prilosec (Omeprazole)
Tagament (Cimitadine) Prevacid (Lansoprazole)
Dobutamine Milrinone
Zantac (Ranitidine)

 OUTCOMES: Lived Expired
 All Feedings (ml) prior to GSTP:

NEC Stage II

NEC Stage III

Surgery Date:___________

_________ ml

Feeding Type
Total Amount (ml)
% of Total
Feedings

Full Feedings post NEC:

__________140 cc/kg/d

PCA:_______weeks
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 Micro  Labs

Laboratory values: 3 days prior/post NEC
DOL

0

1

2

3

From: ________to ___________
4

5

DATE
WEIGHT
Transfusion: RBC
Transfusion:
Platelet
TYPE of FEEDING
Total ml
TYPE of FEEDING
Total ml
TYPE of FEEDING
Total ml
TYPE of FEEDING
Total ml
Emesis
Enteral fluid
(mL/kg/d)
WBC
Platelet Count
Mean Plt Volume
Platelet Mass
(MPV x Plt Count)
Abs Neutrophil
Count
% Myelocytes
% Metamyelocytes
% Bands
% Segs or
Neutrophils/Polys
I :T Immature cells
Total
CRP
pH
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6

7

8

9

10

11

